Prostate Cancer Recurrent Clinical Trial
Official title:
Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer
To development of clinical assessment technique using multi-radiotracer positron emission
tomography/magnetic resonance (PET/MR) in prostate cancer
- to establish the optimal imaging technique of PET/MR using multiple radioactive tracers
for prostate cancer
- to establish the imaging biomarker using PET/MR for clinical assessment of prostate
cancer and early detection of recurrent prostate cancer
To establish the optimal imaging technique of PET/MR using multiple radioactive tracers for
prostate cancer
- Recruiting 30 patients with prostate cancer ahead to radical prostatectomy
- PET/MR using 18F-choline with dedicated prostate MRI in all patients
- PET/MR using 18fluoride(F)-fluorodeoxyglucose(FDG)in all patients after 2-7 days
- PET/CT using 18F-FDG in all patient immediate after 18F-FDG PET/MR
- outcome assessment: comparison of scan time, image quality, tumor detection rate,
standardized uptake values of lesions
- establishing optimal imaging technique for prostate PET/MR
To establish the imaging biomarker using PET/MR for clinical assessment of prostate cancer
- comparison of findings on PET/MR, MRI and PET/CT with pathological mapping after
radical prostatectomy
- outcome assessment: accuracy of PET/MR for localization and staging of prostate cancer
compared with MRI only and PET/CT only
To establish the imaging biomarker using PET/MR for early detection of recurrent prostate
cancer
- Recruiting 15 patients with recurrent prostate cancer treated by surgery, hormone, or
radiation therapy
- Recruiting 15 patients with treated prostate cancer without recurrence
- PET/MR using 18F-choline with dedicated prostate MRI in all patients
- PET/MR using 18F-FDG in all patients after 2-7 days
- PET/CT using 18F-FDG in all patient immediate after 18F-FDG PET/MR
- comparison of findings on PET/MR, MRI, and PET/CT with clinical data in two patient
groups with or without recurrent prostate cancer
- outcome assessment: accuracy of PET/MR for early detection and localization of
recurrent prostate cancer compared with MRI only and PET/CT only
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05848011 -
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02562131 -
PET-MR-PSA Prostate Cancer Recidive Study
|
||
| Completed |
NCT04134130 -
The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer
|
N/A | |
| Recruiting |
NCT03507595 -
Evaluation of the Metastasis and Recurrence of Prostate Cancer
|
||
| Active, not recruiting |
NCT04983628 -
Molecular Profiling in Prostate Cancer
|
||
| Completed |
NCT03739684 -
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT04686188 -
Exploring the Mechanisms and Dynamics of Clonal Evolution Leading to Recurrence in Prostate Cancer
|
||
| Active, not recruiting |
NCT04114825 -
Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05646550 -
Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT04876755 -
MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01857037 -
Post-radiation Prostate Cancer Local Recurrences: Detection With Histoscanning™ and MRI
|
N/A | |
| Active, not recruiting |
NCT03444844 -
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04102553 -
F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
|
Phase 3 | |
| Completed |
NCT03443609 -
Study of 68Ga-HBED-PSMA PET/CT and Conventional Imaging in Occult Biological Relapse Prostate Cancer
|
N/A | |
| Recruiting |
NCT05036226 -
COAST Therapy in Advanced Solid Tumors and Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04324983 -
Identification of Predictive Biomarkers
|
N/A | |
| Completed |
NCT02176161 -
Metformin Prostate Cancer Adjuvant Trial
|
Phase 2 | |
| Active, not recruiting |
NCT04734184 -
A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT04312191 -
Using Meditation for Oncology Anxiety
|
N/A |